NCT06059287 is a NA clinical trial of Henagliflozin in Obesity, sponsored by RenJi Hospital.

Who is sponsoring NCT06059287?

NCT06059287 is sponsored by RenJi Hospital.

What drugs are being tested in NCT06059287?

Interventions in NCT06059287: Henagliflozin, Metformin.

What condition does NCT06059287 study?

NCT06059287 studies Obesity, Type 2 Diabetes, Sodium-glucose Co-transporter-2 Inhibitor, Myocardial Fibrosis, Magnetic Resonance Imaging.

Is NCT06059287 still recruiting?

NCT06059287 is currently status unknown. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT06059287

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics

Status unknown NA Last updated 28 September 2023

What this trial tests

NA trial testing Henagliflozin in Obesity in 64 participants. Status unknown.

Timeline

1 October 2023

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	RenJi Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	64
Start date	1 October 2023
Primary completion	31 December 2025
Estimated completion	31 December 2025

Drugs / interventions tested

Henagliflozin — full drug profile →
Metformin (metformin) — full drug profile →

Conditions studied

Obesity — all drugs for Obesity →
Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sodium-glucose Co-transporter-2 Inhibitor — all drugs for Sodium-glucose Co-transporter-2 Inhibitor →
Myocardial Fibrosis — all drugs for Myocardial Fibrosis →

Sponsor

RenJi Hospital

Who can join

Adults 18 to 75, any sex, with Obesity or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, randomized, open-label, active drug controlled clinical trial that aims to compare the effects of henagliflozin or metformin on myocardial tissue level characteristics in type 2 diabetes patients with obesity. Eligible subjects with type 2 diabetes before randomisation and fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomised in a 1:1 ratio to henagliflozin 10 mg once a day or metformin 1000 mg twice a day and treated for 24 weeks. The study includes five visits.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Metabolic reprogramming in fibrosis-related diseases: underlying mechanisms and therapeutics.
Feng Y, Zhang X, Wang XJ, Chen C. · · 2026 · PMID 42247154 · DOI 10.1186/s43556-026-00490-9

Verify or expand the search:

Other trials of Henagliflozin

Trials testing the same drug.

NCT06085703 — Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel C · NA · completed
NCT06218342 — Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease · Phase 4 · unknown
NCT06216340 — Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes · Phase 4 · not yet recruiting
NCT06031389 — Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis · NA · unknown
NCT06187727 — Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction · Phase 4 · completed

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06059287 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06059287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing